Physician profile
Nelson John D Silva
NPI 1477529790
$3,993.96
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,059 · 2020: $1,235 · 2021: $1,686 · 2022: $13.96.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $429.94 | 2019-2021 | |
| Pfizer INC. | $394.58 | 2019-2020 | |
| Abbvie INC. | $394.12 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $385.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $302.82 | 2019-2021 | |
| Amarin Pharma, INC. | $229.56 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $218.78 | 2019-2021 | |
| Lilly USA, LLC | $193.91 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $165.76 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $159.56 | 2020-2021 | |
| Allergan, INC. | $129.62 | 2019-2020 | |
| Esperion Therapeutics, INC. | $116.58 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $110.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $109.63 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.62 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $67.57 | 2021 | |
| Sanofi-Aventis U.S. LLC | $66.19 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.38 | 2019-2020 | |
| Amgen INC. | $55.60 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $45.40 | 2020 | |
| Fidia Pharma USA INC. | $36.21 | 2019 | |
| Circassia INC. | $33.75 | 2019 | |
| Hikma Pharmaceuticals USA | $26.42 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $24.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.95 | 2021 | |
| Philips North America LLC | $16.41 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.17 | 2019 | |
| Almatica Pharma LLC | $14.54 | 2021 | |
| Glaxosmithkline, LLC. | $14.27 | 2019 | |
| Shire North American Group INC | $13.86 | 2019 | |
| Mylan Specialty L.P. | $13.70 | 2019 | |
| Eisai INC. | $12.22 | 2021 | |
| Horizon Therapeutics Plc | $12.09 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.79 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson D Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.